8-K: Kineta and TuHURA Biosciences Stockholders Approve Merger, Paving Way for Combined Immuno-Oncology Entity

Kineta, Inc. and TuHURA Biosciences, Inc. stockholders have overwhelmingly approved the proposed merger and related proposals, signaling a significant step towards combining their immuno-oncology development efforts.

Summary

• Kineta, Inc. held a Special Meeting of Stockholders on June 23, 2025, where stockholders voted on three proposals related to the merger with TuHURA Biosciences, Inc.
• As of May 15, 2025, the record date, 13,540,355 shares of Kineta's common stock were issued and outstanding, with 7,441,449 shares (approximately 55%) present or represented by proxy, constituting a quorum.
• Proposal 1, the adoption of the Merger Agreement, was approved with 7,317,175 votes For, 45,968 Against, and 78,306 Abstain/Withheld.
• Proposal 2, an advisory (non-binding) vote on Mergers-related compensation for named executive officers, was approved with 6,838,347 votes For, 283,607 Against, and 319,495 Abstain/Withheld.
• Proposal 3, the adjournment of the Special Meeting, was not acted upon as it was not necessary.
• TuHURA Biosciences, Inc. stockholders also approved all proposals at their Special Meeting on June 23, 2025, including an increase in authorized shares to 200 million and reincorporation in Delaware.
• The parties anticipate the merger will close as soon as possible following the satisfaction or waiver of any remaining closing conditions.
• Kineta had previously announced a corporate restructuring in February 2024, including a significant workforce reduction and suspension of new patient enrollment in its VISTA-101 Phase 1/2 clinical trial for KVA12123, to reduce expenses and preserve cash while exploring strategic alternatives.

Sentiment

Score: 7

Explanation: The successful stockholder approval of the merger for both Kineta and TuHURA Biosciences is a strong positive development, providing a clear path forward for the combined entity and its immuno-oncology pipeline. While Kineta had faced prior financial difficulties, this merger offers a strategic resolution. The document highlights standard risks associated with mergers and drug development, but the core outcome is favorable for the transaction's progression.

Positives

• Kineta stockholders overwhelmingly approved the Merger Agreement, indicating strong support for the strategic transaction.
• The approval of the merger provides a path forward for Kineta, which had previously undergone significant restructuring and suspended clinical trial enrollment due to cash preservation needs.
• The combined entity will leverage TuHURA's Phase 3 immuno-oncology pipeline, including IFx-2.0, and Kineta's clinical-stage VISTA blocking immunotherapy, KVA12123, potentially creating a more robust development portfolio.
• TuHURA stockholders also approved all related proposals, including an increase in authorized shares and reincorporation in Delaware, facilitating the merger.
• The merger is anticipated to close 'as soon as possible,' suggesting a timely completion.

Negatives

• Kineta had previously undergone a significant corporate restructuring in February 2024, including a workforce reduction and suspension of new patient enrollment in its VISTA-101 Phase 1/2 clinical trial, indicating prior financial distress and operational challenges.
• The merger is subject to remaining closing conditions, including TuHURA's completion of a 'Concurrent Investment,' which introduces a dependency and potential for delay if not met.
• The document highlights risks related to Kineta's cash level and ability to continue as a going concern if the merger is not successfully completed.

Risks

• Failure to complete the Mergers on anticipated terms and timing, or at all.
• Unforeseen liabilities or adverse tax treatment related to the Mergers.
• Uncertainties related to Kineta's cash level and ability to continue as a going concern if the merger is not completed.
• Fluctuations in the price of TuHURA Common Stock and Kineta Common Stock before the completion of the Mergers.
• Risks relating to the amount of Kineta's Estimated Net Working Capital Amount at the Closing, including potential reduction or adjustments to the Merger Consideration or failure of the condition that Kineta's Estimated Net Working Capital Deficit not exceed $6,000,000.
• Uncertainties regarding access to available financing, including the Concurrent Investment, to complete the Mergers.
• Occurrence of any event, change, or circumstance that could lead to the termination of the Merger Agreement.
• Risk that the Mergers do not qualify as a reorganization under the Code.
• Risk that, if the Mergers or another strategic transaction is not successfully completed, Kineta's board of directors may decide to pursue a dissolution and liquidation of Kineta.
• Potential adverse effects of the announcement or pendency of the transaction on Kineta's or TuHURA's business relationships, competition, business, financial condition, and operating results.
• Risks that the Mergers disrupt current plans and operations of Kineta or TuHURA and the ability to retain and hire key personnel.
• Risks related to diverting management teams' attention from ongoing business operations.
• Outcome of any legal proceedings that may be instituted against Kineta or TuHURA related to the Merger Agreement or the transaction.
• Ability of TuHURA to successfully integrate Kineta's business or fully realize anticipated synergies or other benefits from the Mergers.
• Ability of TuHURA to implement its plans, forecasts, and expectations with respect to Kineta's business or the combined business.
• Risks associated with third-party contracts containing consent and/or other provisions that may be triggered by the Mergers.
• Potentially significant amount of any costs, fees, expenses, impairments, or charges related to the Mergers.
• Risk of no amounts being payable under the Disposed Asset Payment Right.
• Potential dilution of TuHURA and Kineta stockholders' ownership percentage of TuHURA after the Mergers.
• TuHURA and Kineta directors and executive officers having interests in the Mergers that are different from, or in addition to, the interests of stockholders generally.
• Macroeconomic conditions and geopolitical uncertainty in the global economy.
• Uncertainty in the growth of the biopharmaceutical sector.
• Highly competitive industries TuHURA and Kineta operate in.
• Actions by U.S. or foreign governments, such as additional export restrictions or tariffs.
• Legislative, regulatory, and economic developments affecting Kineta's and TuHURA's businesses.
• Evolving legal, regulatory, and tax regimes.
• Restrictions during the pendency of the Mergers that may impact Kineta's or TuHURA's ability to pursue certain business opportunities or strategic transactions.
• Unpredictability and severity of catastrophic events, including acts of terrorism or outbreak of war or hostilities.
• Uncertainties in obtaining successful clinical results for product candidates and unexpected costs.
• Risks related to the failure to realize any value from product candidates and preclinical programs.

Future Outlook

The companies anticipate the merger will close as soon as possible following the satisfaction or waiver of any remaining closing conditions. Post-merger, TuHURA plans to initiate a single randomized placebo-controlled Phase 3 registration trial for its lead innate immune agonist, IFx-2.0, as an adjunctive therapy to Keytruda in first-line treatment for advanced or metastatic Merkel Cell Carcinoma. The combined entity will also continue to develop Kineta's KVA12123, a VISTA blocking immunotherapy, and other preclinical programs.

Management Comments

• The parties anticipate that the Merger will close as soon as possible following the satisfaction or waiver of any remaining closing conditions.
• TuHURA and Kineta caution investors that any forward-looking statements... are only predictions and involve known and unknown risks and uncertainties, many of which are beyond TuHURA’s and Kineta’s control, and could cause actual results to differ materially...

Industry Context

The merger between Kineta and TuHURA Biosciences reflects a trend in the biopharmaceutical sector where smaller, clinical-stage companies combine to consolidate pipelines, resources, and expertise, particularly in competitive areas like immuno-oncology. Both companies are focused on addressing cancer immune resistance, a critical challenge in cancer therapy. TuHURA's focus on overcoming primary resistance with IFx-2.0 and Kineta's VISTA blocking immunotherapy, KVA12123, represent distinct but complementary approaches within the broader field of checkpoint inhibitors and T-cell focused therapies. The combined entity aims to enhance its position in developing next-generation immunotherapies.

Comparison to Industry Standards

• The document does not provide specific financial or clinical performance metrics for direct comparison to industry benchmarks or specific comparable companies' projects and results.
• TuHURA's IFx-2.0 is being prepared for a Phase 3 trial as an adjunctive therapy to Keytruda (pembrolizumab), a widely recognized checkpoint inhibitor from Merck.
• Kineta's KVA12123 is a novel VISTA blocking immunotherapy, a different mechanism of action compared to PD-1/PD-L1 inhibitors like Keytruda, which the document states is 'differentiated and complementary with T cell focused therapies.' However, no comparative efficacy or safety data against specific industry standards or competitor drugs are presented in this filing.

Corporate Governance

Legal Proceedings

• The outcome of any legal proceedings that may be instituted against Kineta or TuHURA related to the Merger Agreement or the transaction.

Stakeholder Impact

• Shareholders (Kineta & TuHURA): The merger approval provides a strategic path forward, potentially leading to a more robust combined entity. However, there is a risk of dilution for existing shareholders of both companies due to the merger structure and TuHURA's authorized share increase. Kineta shareholders faced the risk of dissolution and liquidation if the merger failed.
• Employees (Kineta): Kineta previously underwent a significant workforce reduction in February 2024 as part of its restructuring. The merger may bring stability or further integration-related changes.
• Patients: The merger aims to accelerate the development of novel immunotherapies, potentially benefiting patients with advanced solid tumors and Merkel Cell Carcinoma through the combined pipeline.

Next Steps

• Satisfaction or waiver of any remaining closing conditions for the merger.
• Completion of TuHURA's Concurrent Investment.
• Closing of the merger between TuHURA Biosciences, Inc. and Kineta, Inc.
• TuHURA to initiate a single randomized placebo-controlled Phase 3 registration trial of IFx-2.0.
• TuHURA and Kineta will report final voting results in Current Reports on Form 8-K.

Key Dates

Recommendation

Keywords

Kineta, TuHURA Biosciences, Merger Agreement, Stockholder Vote, SEC Filing, 8-K, Biotechnology, Immuno-oncology, Cancer Immunotherapy, Clinical-stage, Phase 3, KVA12123, IFx-2.0, VISTA blocking, Merkel Cell Carcinoma, Checkpoint Inhibitors, Corporate Restructuring, Strategic Alternatives, Delaware Reincorporation, Authorized Shares